Anti-inflammatory Peptides Market

The global anti-inflammatory peptides market size is estimated to register a considerable CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the rising prevalence of disorders including psoriasis, multiple sclerosis, autoimmune diseases, and inflammatory bowel diseases.

Increasing awareness among patients regarding the timely treatment of such disorders is another key factor driving the market growth.

Anti-inflammatory peptides are small but useful elements that suppress or slow down the inflammation of a mammal’s skin, mucous membranes, and injury in the lungs’ air spaces. As per the reports by the World Psoriasis Day Consortium, approximately 130 million people are affected by this disease globally which is about 3% to 4% of the total population. One of the reports by the World Health Organization (WHO) states that about 30 out of 100,000 individuals are affected by multiple sclerosis. The two major inflammatory bowel diseases that are most common are ulcerative colitis and Crohn’s disease as their prevalence are more in the urban areas as compared to rural areas.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing geriatric population base leads to weakening of natural immunity in the direction of the pro-inflammatory status of the human body, which is expected to drive the market growth.
• Adoption of unhealthy lifestyle among a large number of the global population coupled with increasing obesity among them are expected to propel the market during the forecast period.
• Presence of advanced and well-established healthcare infrastructures in the developed regions is anticipated to drive the market expansion in the coming years.
• Expiration of patents of branded drugs coupled with side-effects caused due to anti-inflammatory drugs are key challenges that can hamper the market growth.
• Ongoing research to discover new and effective anti-inflammatory peptides is projected to create lucrative opportunities for market growth during the forecast period.

Scope of the Report

The report on the global anti-inflammatory peptides market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights

Cardiovascular diseases segment is expected to dominate the market

On the basis of applications, the global anti-inflammatory peptides market is segmented into gastrointestinal diseases, cardiovascular diseases, neurological diseases, dermatological diseases, ophthalmological & orthino diseases, renal diseases, transplantation, respiratory diseases & pulmonary, and rheumatological & autoimmune diseases. Among all the segments, the cardiovascular diseases segment held a major share of the market in 2019 and is expected to dominate the market during the forecast period. The segment growth is attributed to the global increasing incidence of cardiovascular diseases among a large number of the global population.

Asia Pacific is anticipated to expand at a lucrative growth rate

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounted for a key share of the market in 2019 and is projected to constitute a considerable market share during the projected period attributed to the presence of strong research & development, technologically advanced systems, and high awareness levels among the patients in the region. Moreover, other factor contributing to the segment growth is due to the increasing prevalence of psoriasis and multiple sclerosis. As per the survey in 2013 by the National Psoriasis Foundation, approximately 7.6 million individuals are affected with psoriasis and 400,000 new cases were registered in the same year in the U.S.

On the other hand, the market in Latin America is also expected to witness a healthy growth rate in the coming years due to the rise of public and private associations, which leads to an increase in investment in the market. However, the market of Asia Pacific is anticipated to expand at a lucrative growth rate during the projected period attributed to the improvement of healthcare infrastructure at a fast pace in the region. Some other major factors driving the market expansion are the increasing level of awareness among patients and the rise in the number of patients in the region.

Segments

The global anti-inflammatory peptides market has been segmented on the basis of

Applications

• Gastrointestinal Diseases
• Cardiovascular Diseases
• Neurological Diseases
• Dermatological Diseases
• Ophthalmological & Orthino Diseases
• Renal Diseases
• Transplantation
• Respiratory Diseases & Pulmonary
• Rheumatological & Autoimmune Diseases

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Abbvie Corp.
• Novartis AG
• Merck Serono
• Rogne Bioscience
• F4 Pharma
• Digna Biotech
• Araim Pharmaceuticals, Inc.
• Mylan Pharmaceuticals

Competitive Landscape

Key players competing in the global anti-inflammatory peptides market are Abbvie Corp.; Novartis AG; Merck Serono; Rogne Bioscience; F4 Pharma; Digna Biotech; Araim Pharmaceuticals, Inc.; and Mylan Pharmaceuticals. Many of these players have adopted business strategies such as development of novel drugs, launch of new products, technology advancement, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.